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Muscle-specific loss of Bmal1 leads to
disrupted tissue glucose metabolism and
systemic glucose homeostasis
Brianna D. Harfmann1,2, Elizabeth A. Schroder1,2, Maureen T. Kachman3, Brian A. Hodge1,2,4, Xiping Zhang1,2,4
and Karyn A. Esser1,2,4*

Abstract
Background: Diabetes is the seventh leading cause of death in the USA, and disruption of circadian rhythms is
gaining recognition as a contributing factor to disease prevalence. This disease is characterized by hyperglycemia
and glucose intolerance and symptoms caused by failure to produce and/or respond to insulin. The skeletal muscle
is a key insulin-sensitive metabolic tissue, taking up ~80 % of postprandial glucose. To address the role of the
skeletal muscle molecular clock to insulin sensitivity and glucose tolerance, we generated an inducible skeletal
muscle-specific Bmal1−/− mouse (iMSBmal1−/−).
Results: Progressive changes in body composition (decreases in percent fat) were seen in the iMSBmal1−/− mice
from 3 to 12 weeks post-treatment as well as glucose intolerance and non-fasting hyperglycemia. Ex vivo analysis
of glucose uptake revealed that the extensor digitorum longus (EDL) muscles did not respond to either insulin or
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) stimulation. RT-PCR and Western blot analyses demonstrated
a significant decrease in mRNA expression and protein content of the muscle glucose transporter (Glut4). We also
found that both mRNA expression and activity of two key rate-limiting enzymes of glycolysis, hexokinase 2 (Hk2) and
phosphofructokinase 1 (Pfk1), were significantly reduced in the iMSBmal1−/− muscle. Lastly, results from metabolomics
analyses provided evidence of decreased glycolytic flux and uncovered decreases in some tricarboxylic acid (TCA)
intermediates with increases in amino acid levels in the iMSBmal1−/− muscle. These findings suggest that the muscle
is relying predominantly on fat as a fuel with increased protein breakdown to support the TCA cycle.
Conclusions: These data support a fundamental role for Bmal1, the endogenous circadian clock, in glucose metabolism
in the skeletal muscle. Our findings have implicated altered molecular clock dictating significant changes in altered
substrate metabolism in the absence of feeding or activity changes. The changes in body composition in our model
also highlight the important role that changes in skeletal muscle carbohydrate, and fat metabolism can play in systemic
metabolism.
Keywords: Glucose metabolism, Skeletal muscle, Circadian rhythm

Background
Glucose metabolism in skeletal muscle requires regulation
at multiple steps including glucose uptake, glucose storage, and glucose oxidation or glycolysis. At the cellular
level, glucose is transported from the blood into the cells
through glucose transporters, and once in the cell, it is
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either stored (glycogenosis) or oxidized (glycolysis). Normal glucose metabolism is crucial in regulating glucose
homeostasis and providing energy for cells [20]. Dysfunction in glucose metabolism is strongly associated with
metabolic diseases such as insulin resistance and diabetes
[4, 7, 15]. These disease states have also been linked to circadian rhythms, as disruption in circadian rhythms can
lead to development of metabolic disease [14, 16, 29].
Circadian rhythms are approximate 24-h oscillations in a
variety of outputs including sleep/wake cycles, metabolism,
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and many aspects of cellular function. Circadian rhythms
are generated by a transcription-translation feedback loop
known as the molecular clock. Simply described, this clock
has positive limb factors, brain and muscle arnt-like protein
1 (Bmal1) and circadian locomotor output cycles kaput
(Clock), and negative limb genes period (period 1 and 2
(Per1/2)) and cryptochrome (Cry1/2) [17, 32]. Bmal1 and
Clock are transcribed and translated and heterodimerize in
the nucleus of the cell. The BMAL1-to-CLOCK heterodimer then binds E-box elements in the promoter sequences
of Per1/2 and Cry1/2 and promotes transcription. Per1/2
and Cry1/2 are transcribed and then translated in the cytoplasm. Then, PER1/2 and CRY1/2 dimerize/heterodimerize
and translocate to the nucleus where they have an inhibitory effect on the activity of BMAL1-to-CLOCK. The
inhibition is eventually lifted, however, as PER1/2 and
CRY1/2 protein is degraded by E3 ubiquitin ligases. In this
manner, a cycle of approximately 24 h is generated [10, 35].
BMAL1-to-CLOCK clock can also bind the E-box elements
of genes outside of the molecular clock (clock-controlled
genes) allowing the molecular clock to govern physiological
and behavioral processes. Since the molecular clock is
present in almost every cell of the body, the modulation of
specific clock-controlled genes means that circadian
rhythms regulate time-of-day tissue-specific functions and
that disruption of the molecular clock in cells does alter cell
function [24, 33, 34]. As previously stated, circadian
rhythms have an important role in metabolism, and consequently metabolism is a key function regulated by the molecular clock in a tissue-specific manner [2, 13, 19, 27, 36].
A recent bioinformatics study from our lab identified
1628 circadian mRNAs in skeletal muscle with 62 % of
these genes having metabolic roles. Carbohydrate metabolism was notably one of the enriched circadian metabolic
functions in skeletal muscle [13]. We found that the circadian genes involved in carbohydrate metabolism were
downregulated by the loss of Bmal1. In contrast, genes involved in lipid metabolism were significantly upregulated in
this model suggesting that loss of Bmal1 only in the skeletal
muscle contributes to selective substrate utilization independent of circadian behavior. Skeletal muscle is responsible for approximately 80 % of glucose uptake in the
postprandial state; therefore, it is critical for maintaining
blood glucose homeostasis [6, 11]. Thus, the purpose of the
current study was to use our inducible mouse model of the
skeletal muscle-specific Bmal1 knockout to test the effect
of disruption of the clock in the adult mouse on tissue glucose metabolism, downstream substrate metabolomics, as
well as whole body metabolic parameters.

Methods
Ethical approval

All experimental procedures were done in accordance
with the institutional guidelines for the care and use of

Page 2 of 13

laboratory animals and approved by the University of
Kentucky Institutional Animal Care and Use Committee.
Animal care and use

Inducible skeletal muscle-specific Bmal1 knockout mice
were generated as previously described [13]. We obtained the skeletal muscle-specific tamoxifen inducible
Cre recombinase mouse from the Center for Muscle
Biology at the University of Kentucky. This mouse has a
Cre recombinase flanked by two mutated estrogen receptors and is driven by a human skeletal actin promoter. Past work confirmed the efficacy of this mouse
for muscle-specific gene recombination in adult mice
[21]. The tamoxifen inducible Cre recombinase mouse
was crossed with the Bmal1-floxed mouse acquired
through Jackson Labs (B6, 1294(Cg)-Arntltm1Weit/J), to
generate the inducible skeletal muscle-specific Bmal1floxed mouse (iMSBmal1fl/fl). Activation of Cre recombination was done by intraperitoneal injections of tamoxifen
(2 mg/day) for five consecutive days when the mice
reached 12 weeks. This age is chosen to eliminate any effects that the lack of Bmal1 might have on skeletal muscle
development and the rapid growth that occurs during
post-natal maturation. Controls were vehicle (15 % ethanol in sunflower seed oil) treated with Cre+/−:Bmal1flox/flox
mice. Recombination specificity was confirmed and is
demonstrated in Hodge et al. [13]. Prior to experimentation, mice were housed in 14:10, light-to-dark conditions.
All experiments were performed 3–5 weeks posttreatment. Echo-MRI was also performed at 10–12 weeks
post-treatment. Both male and female mice were used in
this study. Mice were euthanized prior to glucose uptake
experiments and tissue collection. Euthanasia was performed using anesthesia followed by cervical dislocation.
Echo-MRI

Body composition was quantified in conscious mice at
both 3–5 and 10–12 weeks post-treatment using
EchoMRI Quantitative Magnetic Resonance Body Composition Analyzer (Echo Medical Systems, Houston,
Texas) (mouse numbers n = 6 female iMSBmal1+/+ to n =
7 male iMSBmal1+/+ to n = 8 female iMSBmal1−/−: n = 10
male iMSBmal1−/−).
Glucose tolerance tests and blood work

Glucose tolerance tests [n = 8/group (two females and
six males) in both groups] were performed 2 h after
lights-off (ZT14), a time at which glucose tolerance is
highest [18]. Mice were fasted 6 h prior to the start of
the test, and all measurements were done with an
AlphaTRAK glucometer (Abbott Animal Health). A
measurement was taken prior to injection of a bolus of glucose (0 min). Mice were injected by intraperitoneal injection with 2 mg/kg glucose, and additional measurements
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were taken at 15, 30, 60, 90, and 120 min post-injection. All
fasting blood measures were obtained after a 6-h fast.
Fasting blood glucose (n = 8/group (2 females and 6
males in both groups)) was measured with the AlphaTRAK glucometer, and fasting insulin (n = 7/group (3
females and 4 males in both groups)) was measured
by collecting blood from the tail vein of the mice and
running a colorimetric ELISA (Crystal Chem). Nonfasting blood glucose was measured by measuring
blood glucose every 4 h for 24 h and averaged [n = 4
per time point; CT18 iMSBmal1+/+ n = 2 F/2 M;
iMSBmal1−/− n = 2 F/2 M; CT22 iMSBmal1+/+ n = 4
M; iMSBmal1−/− n = 2 F/2 M; CT26 iMSBmal1+/+ n =
2 F/2 M; iMSBmal1−/− n = 1 F/3 M; CT30 iMSBmal1+/+
n = 1 F/3 M; iMSBmal1−/− n = 1 F/3 M; CT34
iMSBmal1+/+ n = 1 F/3 M; iMSBmal1−/− n = 1 F/3 M]
Glucose uptake experiments

All solutions in this experiment were bubbled with 95 %
O2/5 % CO2 and kept at 35 °C. Extensor digitorum
longus (EDL) muscles were excised from each leg of the
mice [n = 8 (2 F/6 M)/group for insulin stimulation; n =
5 all females/group for 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) stimulation] and placed in a recovery media (Krebs Henseleit Buffer (KHB) with 0.1 %
bovine serum albumin, 2 mM sodium pyruvate, 6 mM
mannitol) with or without 2000 μU/mL insulin or
2 mmol/L AICAR. After 30 min, muscles were transferred to an incubation buffer (KHB with 0.1 % bovine
serum albumin, 2 mM sodium pyruvate, 6 mM mannitol, 1 mM 2-deoxy-D-glucose, 2.25 μL/mL [3H]-2-deoxyglucose, 2 μL/mL [14C]-mannitol) with or without
2000 μU/mL insulin or 2 mmol/L AICAR (consistent
with what the muscle was exposed to in recovery media)
for exactly 20 (insulin) or 40 (AICAR) min. Following
this incubation, tissues were flash frozen. Tissue lysates
were prepared, and 100 μL of each sample was added to
a scintillation vial with 5 mL of scintillation fluid
followed by radioactivity measurement in a scintillation
counter.
Real-time PCR (RT-PCR)

RNA was isolated from gastrocnemius (GTN) samples
of iMSBmal1+/+ and iMSBmal1−/− mice [n = 7 (3 F/4
M)/group]. Briefly, 50–100 mg of GTN tissue was homogenized in 1 mL Trizol (Invitrogen). Phase separation,
RNA precipitation and RNA washes, and RNA resuspension were carried out as per manufacturer’s instructions.
RNA was quantified through spectrophotometrically (λ =
260 nm). Total RNA was then used to synthesize cDNA
using a mixture of oligo(dT) primer and random hexamers in SuperScript III First-Strand Synthesis SuperMix
(Invitrogen, Waltham, MA, USA) kit. Expression of glucose transporter type 4 (Glut4), hexokinase 2 (Hk2), and
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phosphofructokinase 1 (Pfk1) was performed using cDNA
and the following Taqman primers (Applied Biosystems):
Mm01245502_m1, Mm00443385_m1, Mm01309576_m1,
Mm99999915_g1, and Mm02343715_g1. RPL26 or
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were used as the internal calibration controls. The
ΔΔCT method was used for the quantification of realtime PCR data. Gene expression in each sample was
shown as the relative value compared to the mean vehicle value in that tissue (GTN).
Western blot analysis

Tissue lysates were made from GTN muscles of
iMSBmal1+/+ and iMSBmal1−/− mice [n = 7 (3 F/4 M)/
group]. Proteins were separated by SDS-PAGE using 4–
15 % Tris-HCl precast gels (BioRad), transferred, and
immunoblotted using routine methods. GLUT4 was detected using a primary monoclonal GLUT4 antibody
(Cell Signaling, #2213) and an AlexaFluor680 goat antirabbit secondary antibody (Invitrogen, #A-21109).
Hexokinase activity assay

Hexokinase activity was measure following as previously
described [30]. GTN tissue [n = 7 (3 F/4 M)/group] was
homogenized in a buffer (1:10, weight to volume) containing 150 mM KCl, 10 mM MgCl2, 5 mM EDTA, and
5 mM β-mercaptoethanol. Samples were centrifuged at
15,000×g for 1 h while experimental solutions A (47 mM
Tris (pH 7.4), 10 mM MgCl2, 0.8 mM NADP, 0.5 mM
glucose, 5.0 mM mercaptoethanol, 0.1 units glucose 6phosphate dehydrogenase) and B were prepared(47 mM
Tris (pH 7.4), 10 mM MgCl2, 0.8 mM NADP, 0.5 mM
glucose, 5.0 mM mercaptoethanol, 0.1 units glucose 6phosphate dehydrogenase, 5 mM ATP, 0.27 mM phosphoglyceric acid). An Eppendorf tube containing
2.45 mL of A or B was made for each tissue sample.
After centrifugation was complete, 0.05 mL of tissue
sample was added to each tube. Absorbance was measured at 30 °C and 340 nM every 2 s for 10 min. Samples were measured in duplicates. As the glycolytic
reaction takes place, NADP is oxidized to form NADPH
which has an absorbance at 340 nm.
Phosphofructokinase activity assay

The same tissue samples [n = 7 (3 F/4 M)/group] used
for the hexokinase activity assay were used for the phosphofructokinase assay. The reaction mixture for this
assay contained 50 mM Tris-HCl (pH 8), 1 mM EDTA,
6 mM MgCl2, 2.5 mM dithiothreitol, 0.16 mM NADH,
1 mM ATP, 1 mM fructose-6-phosphate, 0.4 units aldolase, 2.4 units triose-phosphate isomerase, and 0.4 units
α–glycero-phosphate dehydrogenase. Five microliters of
tissue sample was added to 295 μL of reaction mixture,
and absorbance was read at 25 °C and 340 nM for
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10 min. As the glycolytic reaction takes place, NADH,
which is detectable at 340 nm, is reduced to NAD+ and
absorbance decreases.
Metabolomics data

GTN muscles were dissected and freeze clamped in situ at
ZT14 from anesthetized iMSBmal1+/+ and iMSBmal1−/−
mice [n = 7 (3 F/4 M)/group] at 5 weeks post-treatment.
Flash-frozen samples were sent to the University of Michigan Metabolomics Core Services for targeted metabolomics of glycolysis/tricarboxylic acid (TCA)/nucleotides
involved in central metabolism. Twenty milligrams of
skeletal muscle tissue was extracted first exposing the tissue to liquid nitrogen to harden the sample, then grinding
the tissue in a pre-chilled mortar and pestle until the tissue was deemed adequately disrupted. The ground tissue
was then transferred to a microtube, and metabolites were
extracted with 0.5 mL of a mixture of methanol, chloroform, and water (8:1:1) containing isotope-labeled internal
standards using a probe sonicator at 40 % output power,
20 % duty cycle for 20 s. Samples were allowed to rest at
4 °C for 10 min and then centrifuged at 4 °C, 14,000 rpm
for 10 min. The extracts were removed and placed into an
autosampler vial for mass spec analysis. Ten microliters of
each sample was removed and pooled in a separate autosampler vial for quality control purposes. A series of calibration standards were prepared along with samples to
quantify metabolites.
LC-MS analysis was performed on an Agilent system
consisting of a 1260 UPLC module coupled with an
6520 Quadrupole-Time-of-flight (QTOF) mass spectrometer (Agilent Technologies, CA.) Metabolites were
separated on a 150 × 1 mm Luna NH2 hydrophilic interaction chromatography column (Phenomenex, CA)
using 10 mM ammonium acetate in water, adjusted to
pH 9.9 with ammonium hydroxide, as mobile phase A,
and acetonitrile as mobile phase B. The flow rate was
0.075 mL/min, and the gradient was linear 20 to 100 %
A over 15 min, followed by isocratic elution at 100 % A
for 5 min. The system was returned to starting conditions
(20 % A) in 0.1 min and held there for 10 min to allow for
column re-equilibration before injecting another sample.
The mass spectrometer was operated in ESI-mode with
the following conditions: gas temperature 350 °C, drying
gas 10 L/min, nebulizer 20 psi.
Data were processed using MassHunter Quantitative
analysis version B.07.00. Metabolites in the glycolysis/tricarboxylic acid (TCA)/ppp pathways were normalized to
the nearest isotope-labeled internal standard and quantitated using two replicated injections of five standards to
create a linear calibration curve with accuracy better
than 80 % for each standard. Other compounds in the
analysis were normalized to the nearest internal standard, and the peak areas were used for differential analysis
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between groups. Results from this analysis were used to
identify enriched pathways using the online software
Metaboanalyst 3.0, a comprehensive tool for metabolomic data analysis supported by The Metabolomics
Innovation Center (TMIC), a Genome Canada-funded
core facility.
Activity recordings

Telemetry (Data Sciences International (DSI)) was used
to evaluate changes in cage activity after vehicle/tamoxifen injection. Mice were anesthetized with isoflurane,
and transmitter units (PhysioTel PA-C10; DSI) were implanted. Mice were housed singly and allowed to recover
for 1 week. Data were recorded for 24 h/day, for 3–
4 days weekly up to 10 weeks after vehicle or tamoxifen
treatment. Data were collected and analyzed with DSI
Dataquest ART4.1 telemetry software.
Statistics

For statistics on blood concentrations, glucose tolerance,
RT-PCR, body composition, behavior and enzyme activities, a Student’s t test was utilized. Two-way ANOVA
was used to sex differences in body weight and body
composition and data from glucose uptake experiments
(comparing time exposed to insulin and genotype). Statistical analysis of metabolites was largely performed using
Student’s t test to address differences between genotypes.
To address whether metabolites within the glycolytic
pathway were changed we used Hotelling’s T-squared
test to determine if metabolites were changed between
iMSBmal1+/+ and iMSBmal1−/− mice.

Results
Previous studies examining the germline Bmal1 knock
out mouse demonstrated significant changes in body
weight and systemic metabolic parameters such as the
glucose tolerance test [26]. However, in those studies,
Bmal1 was knocked out in all tissues during embryonic
development. Here, we focus on the loss of Bmal1 in the
skeletal muscle of the adult mouse. For this study, we
generated an inducible skeletal muscle-specific Bmal1
knock out mouse (iMSBmal1−/−; following tamoxifen
treatment) for the targeted disruption of the molecular
clock mechanism only in adult skeletal muscle [13].
We performed the tamoxifen/vehicle injection at 12–
14 weeks of age to avoid the potential problem with
fusion of non-recombined satellite cells during the
maturational, rapid growth phase of skeletal muscle
from 6 to 10 weeks of age. Using this approach, we
found that at 3–5 weeks post-treatment, there was no
statistical difference in body weight or body composition between the two groups (male or female)
(Fig. 1a). However, by 10–12 weeks post-treatment,
the iMSBmal1−/− mice had significantly lower body
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Fig. 1 Body composition but not behavior was altered in the iMSBmal1−/− mice. a Body weight and composition (lean and fat mass) at 3–5 weeks
post-treatment (n = 17 iMSBmal1+/+, n = 20 iMSBmal1−/−). b Body weight and composition (lean and fat mass) at 10–12 weeks post-treatment (n = 12
iMSBmal1+/+, n = 15 iMSBmal1−/−). c Feeding (4 days) at 5 weeks post-treatment (n = 4 iMSBmal1+/+, n = 6 iMSBmal1−/−) and activity (3 days) at 5 and
10 weeks post-treatment (n = 5 iMSBmal1+/+, n = 5 iMSBmal1−/−)

weights (Fig. 1b). Two-way analysis of variance determined that there was no significant interaction between sex and treatment, but there were significant
sex (p < 0.0001) and treatment (p = 0.0079) effects
with males exhibiting the greatest loss in body weight.
Fat mass was also significantly lower in the iMSBmal1
−/−
mice and, while there were differences between
males and females (p = 0.002), there was also a significant treatment effect (0.0012) with no significant
interaction. When analyzing the lean mass data, there
were no statistically significant changes in lean mass
either due to sex or to treatment. Not surprisingly,
the iMSBmal1−/− mice were leaner with a lower percent
fat (18.83 ± 2.2, iMSBmal1+/+; 13.41 ± 1.2, iMSBmal1−/−)

(Fig. 1b). These results indicate that the primary change in
body weight for both male and female mice is through
changes in body fat but that males exhibited a significantly
greater change. It is important to note that these changes
in body composition could not be attributed to altered
feeding or behavior, as there were no detectable differences in net feeding obtained from metabolic cage
analysis in the iMSBmal1−/− mice or net activity obtained from telemetry monitoring at 5 and 10 weeks
post-treatment (Fig. 1c).
We next performed glucose tolerance tests, as well as,
assessed blood glucose and insulin levels. Fasting blood
glucose (Fig. 2a) was not significantly different between
groups [n = 7 (3 F/4 M)/group], but iMSBmal1−/− mice
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Fig. 2 iMSBmal1−/− mice display altered systemic glucose handling. a Fasted blood glucose (n = 8/group (2 females and 6 males in both
groups)). b Fasted blood insulin n = 7/group (3 females and 4 males in both groups). c Glucose tolerance depicted as blood glucose versus time
post-glucose injection and area under the curve (n = 8/group (2 females and 6 males) in both groups). d Non-fasted blood glucose measured
every 4 h for 24 h [n = 4 per time point: CT18 iMSBmal1+/+ n = 2 F/2 M; iMSBmal1−/− n = 2 F/2 M; CT22 iMSBmal1+/+ n = 4 M; iMSBmal1−/− n = 2
F/2 M; CT26 iMSBmal1+/+ n = 2 F/2 M; iMSBmal1−/− n = 1 F/3 M; CT30 iMSBmal1+/+ n = 1 F/3 M; iMSBmal1−/− n = 1 F/3 M; CT34 iMSBmal1+/+ n = 1
F/3 M; iMSBmal1−/− n = 1 F/3 M]

had significantly elevated fasting insulin levels (2-fold
higher) compared to iMSBmal1+/+ mice (Fig. 2b). When
injected with a bolus of exogenous glucose, iMSBmal1−/−
mice exhibited a greater overall increase in blood glucose.
In addition, glucose levels remained elevated for a longer
period of time in the iMSBmal1−/− mice. The combination
of the overall increase in blood glucose, and the extended
time that blood glucose remained elevated in the
iMSBmal1−/− mice, significantly increased the area under
the curve (51.9 % increase) when compared to the control
mice (iMSBmal1+/+) (Fig. 2c). None of the tests on this
cohort of mice showed any difference in response within a
genotype for the male (n = 4) vs. female (n = 3) mice. Analysis of blood glucose levels was also taken from non-

fasted iMSBmal1+/+ and iMSBmal1−/− mice during a
circadian time course collection, every 4 h over a 28-h
period [13]. In this set of experiments, we found that
iMSBmal1−/− mice displayed significantly higher blood
glucose values (~42 %) across every time point collected
relative to iMSBmal1+/+ mice. We used both male and female mice for these experiments (see “Methods” section
for detailed description), and we did not detect any difference in non-fasted blood glucose between either sexes.
These results are plotted for each group, at each time
point in Fig. 2d.
Skeletal muscle is the major site for glucose disposal
in the postprandial state. The measured glucose intolerance, elevated fasting insulin levels, and elevated non-
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fasting blood glucose levels implied a defect in skeletal
muscle glucose uptake. We examined this further by
testing whether the loss of Bmal1 in the skeletal muscle
alters either insulin-stimulated or AICAR-stimulated
glucose uptake pathways in the EDL muscles of
iMSBmal1+/+ and iMSBmal1−/− mice. We found that
there was no difference in basal levels of glucose uptake
but that the insulin-stimulated glucose uptake was significantly impaired in the iMSBmal1−/− mice (Fig. 3a). In
addition, we found that when EDL muscles were treated
with AICAR (n = 5 females/group), glucose uptake increased significantly in the iMSBmal1+/+ muscle but, like
seen with insulin, there was no change in glucose uptake
in the EDL of the iMSBmal1−/− mice (Fig. 3b).
Insulin and AICAR stimulate separate pathways to
facilitate glucose uptake [8]. However, our results are
consistent with a model in which the loss of Bmal1 in the
skeletal muscle leads to altered expression of a common
component to both pathways. We focused on the levels of
Glut4, and we found that in the iMSBmal1−/−, mRNA expression is reduced by 47.2 % and protein content of the
glucose transporter was reduced by 75.5 % relative to that
measured in iMSBmal1+/+ mice (Fig. 4a, b).
Upon entering the muscle cell, glucose is phosphorylated to glucose-6-phosphate by the glycolytic enzyme
HK2. This rapid transition of glucose to glucose-6phosphate allows the cell to maintain a glucose concentration gradient relative to the extracellular fluid to help
sustain glucose influx when GLUT4 is present at the
membrane. In this regard, it has been proposed that
HK2 activity can modulate glucose uptake. We analyzed
GTN muscle microarray data from our circadian dataset
[13]. Signal intensity measured for Hk2 mRNA was
significantly lower in the iMSBmal1−/− mice (Fig. 5a).
We next tested whether there was any change in the enzyme activity of HK2 in the GTN of the iMSBmal1+/+
and iMSBmal1−/− mice (n = 3 females/4 males for each
group) and consistent with the decreased expression, we
found that HK2 activity (uM/g/min) was 49.5 % reduced
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in muscle extracts from iMSBmal1−/− mice (Fig. 5b). Besides having an impact on glucose uptake, HK2 is a ratelimiting enzyme in the glycolytic pathway. In order to
further evaluate glycolytic flux in the iMSBmal1−/− mice,
we examined another rate-limiting enzyme of glycolysis,
phosphofructokinase (Pfk1). Real-time PCR results confirmed that Pfk1 mRNA expression was reduced by
23.3 % in iMSBmal1−/− mice, and like HK2, we found
that enzyme activity for Pfk1 was significantly reduced
by 52.4 % (Fig. 5c, d).
To gain a better sense of metabolite changes in the
iMSBmal1−/− skeletal muscles, we used a targeted metabolomics approach to evaluate glycolytic/TCA-related
metabolites in the GTN muscles the mice [n = 7 ((3 females/4 males)/group)]. All skeletal muscles were flash
frozen in situ with tongs cooled to liquid N2 and shipped
to the Michigan Regional Comprehensive Metabolomics
Resource Core for glycolytic and TCA cycle metabolites.
The results of these assays are provided in Table 1. We
found that glucose levels were significantly elevated within
the muscle of the iMSBmal1−/− mice compared to the
iMSBmal1+/+ mice. In addition, we measured glycogen
using a biochemical assay and found that glycogen was
also significantly increased in the GTN muscles of the
iMSBmal1−/− mice (Table 1). When considered in context
with the decreased Pfk1 activity, this suggests that glucose
is being preferentially stored vs. oxidized in the skeletal
muscle. We also found that metabolites of glycolysis,
including glyceraldehyde 3-phosphate and 2- and 3phopshoglycerate, were significantly lower and phosphoenolpyruvate trended to be lower in the iMSBmal1−/−
mice. Interestingly, levels of lactate were also significantly
elevated in the GTN muscle of iMSBmal1−/− mice.
In addition to changes in glucose and glycolytic intermediates, the metabolomics data revealed significant
changes in a number of amino acids that are known to
have functions associated with the maintenance of TCA
cycle intermediates. The observed changes in metabolites in glycolysis and amino acids suggested we also

Fig. 3 Glucose uptake was diminished in the iMSBmal1−/− mice. a Insulin-stimulated glucose uptake in the EDL muscles using a maximum insulin
dose and 20 min of exposure [n = 8 (2 F/6 M)/group]. b AICAR-stimulated glucose uptake in the EDL muscles after 40 min of exposure incubation
media with or without AICAR n = 5 (5 F)/group
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Fig. 4 Both mRNA and protein expression of the glucose transporter type 4 (Glut4/GLUT4) were decreased in the iMSBmal1-/- mice. a mRNA expression
of Glut4 in the GTN muscle measured using RT PCR. (n = 6). b Protein content of GLUT4 in the GTN muscle was measured as integrated intensity
of the fluorescent bands (n = 7)

examined genes associated with fat metabolism. Analysis
of our microarray data [13] demonstrated an increase in
several genes associated with fat metabolism (Fig. 6a).
We did not detect any significant changes in triglyceride
levels in the GTN, but levels of oleic acid trended
toward lower (p = 0.085) and levels of pantothenate
(vitamin B5), which is used to synthesize coenzyme A
(CoA), were significantly down (p = 0.0093). The list of
the amino acid changes is provided in Table 1, and we
have integrated all the metabolomics data with potential

impact on glycolysis and the TCA cycle as a summary
figure (Fig. 7).

Discussion
Skeletal muscle is a highly metabolic tissue and is primarily responsible for the disposal of glucose in the
postprandial state [6]. Circadian rhythms play an important role in regulating metabolism in a tissue-specific
manner, and recent research demonstrates that disruption of circadian rhythms leads to metabolic dysfunction

Fig. 5 Activity of rate-limiting glycolytic enzymes (HK2 and PFK1) was significantly decreased in the iMSBmal1−/− mice. a mRNA expression of Hk2
obtained from microarray data (n = 6). b Enzymatic activity of the rate-limiting enzyme HK2 in the GTN muscle measured using a spectrophotometric
assay (n = 7). c mRNA expression of the rate-limiting enzyme Pfkm in the GTN muscle (n = 7). d Enzymatic activity of PFKM in GTN muscles
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Table 1 List of metabolites involved in glycolysis, fat oxidation, and TCA cycle in iMSBmal1+/+ and iMSBmal1−/− mice 5 weeks posttreatment [n = 7 (3 F/4 M)/group]

Texts in green are upregulated, p < 0.05; red downregulated, p < 0.05; green italicized trending up; red italicized trending down; and black no change
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Fig. 6 Genes involved in fat metabolism are upregulated in the
iMSBmal1−/− GTN. a Array data revealed that genes important in fat
metabolism in the skeletal muscle are significantly upregulated in the
iMSBmal1−/− GTN. b Triglyceride levels trended toward a decrease in
the iMSBmal1−/− GTN

and disease [5, 13, 31, 34]. Our understanding of the
function of the clock and core molecular clock genes,
such as Bmal1, in skeletal muscle is still quite elementary. In our investigation, we demonstrate that loss of
the core circadian clock gene, Bmal1, solely in adult
skeletal muscle quickly manifests in disrupted glucose
metabolism as demonstrated by impaired glucose uptake
with a concomitant reduction in the muscle glucose
transporter GLUT4 and decreased activities of key ratelimiting enzymes of glycolysis. Disruption of the molecular clock also led to changes in metabolites within the
TCA cycle (citrate to isocitrate), and significant increases
in amino acids and genes that regulate fat metabolism
pointing to altered substrate metabolism for energy and
maintenance of TCA cycle intermediates. Lastly, our
findings demonstrate the contribution of disrupted skeletal muscle metabolism to system homeostasis including
hyperglycemia in the non-fasting condition, glucose
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intolerance, and altered body composition in the absence
of feeding or physical activity changes.
Our work demonstrates that loss of Bmal1 only in the
skeletal muscle can significantly affect glucose uptake
into the skeletal muscle and implicates that these effects
of Bmal1 are likely mediated through regulation at least
two different levels. First, we found that both insulinstimulated glucose uptake and AICAR-stimulated glucose uptake are diminished with loss of Bmal1 in the
skeletal muscle. While these two signaling pathways for
glucose uptake are distinct, the end target, GLUT4, is
common and is significantly downregulated at the protein level [1, 5, 28]. In addition, we found that the enzyme activity for HK2 was almost 50 % lower compared
to control levels. This is consistent with our findings of
higher free glucose levels in the cell and would, in turn,
function to decrease the concentration gradient between
the inside and the outside of the muscle cell and thus,
function to lower the rate of facilitated transport via
GLUT4. In a study by Fueger et al. in 2003, they demonstrated that partial Hk2 knockdown was enough to result
in a decrease in exercise-stimulated glucose uptake [9].
We also found that one of the primary glycolytic ratelimiting enzymes, Pfk1 [3, 22], was reduced at the
mRNA level with an even more dramatic decrease in
enzyme activity in the iMSBmal1−/− mice. Lowered Pfk1
activity coupled with observations of lowered pyruvate
dehydrogenase (PDH) activity by Dyar et al. [5] provides
strong evidence for a significantly lower flux through
glycolysis. This change in glycolytic flux has been proposed to have a secondary impact on glucose uptake by
muscle [25]. Recent studies have also demonstrated the
potential for a confounding effect due to tamoxifen
treatment on metabolic parameters. In the most recent
study, Hesselbarth et al. demonstrated transient changes
in fat mass with a significant decrease at 1 week followed
by a significant increase at 5 weeks post-treatment in
C57BL/6NTac male mice [12]. These findings are very
different compared to our results in which the tamoxifentreated mice, male and female, exhibit no early change in
body fat but are significantly leaner 10 weeks. The fact
that our mice are leaner, and not fatter, at the 10 weeks
time period strongly supports our conclusion that loss of
Bmal1 in muscle is the upstream mediator of the changes
in systemic body composition.
Using a targeted metabolomic approach, we were also
able to show that loss of Bmal1 only in adult skeletal
muscle is sufficient to induce significant decreases in
metabolites within the glycolytic pathway and TCA cycle
with concomitant increases in selective amino acids that
can function to support the TCA cycle intermediates.
Decreased levels of 2-/3-phosphoglycerate and glycerol
3-phosphate in combination with trending decreases in
phosphoenolpyruvate are consistent with a decreased
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Fig. 7 Summary of changes linked to substrate oxidation in the skeletal muscle. Metabolomics data, enzymatic activity data, glycogen data, and
triglyceride data are included. Green upregulated, red downregulated, green italicized trending up, red italicized trending down, and black no change

glycolytic flux and lower PFK1 activity. The work from
Dyar et al. [5] showed that rates of PDH activity were
lower in muscle of Bmal1 knockout mice so it was not
surprising to find that levels of lactate were elevated
even in the context of decreased glycolytic flux. With
the exception of a reduction in citrate/isocitrate, we did
not see changes in most TCA intermediates (e.g., oxaloacetate, α-ketogluterate, and fumerate) but many amino
acids were elevated suggesting that proteins were being
metabolized to support the need for pyruvate, oxaloacetate, α-ketogluterate, fumerate, and succinate. Amino
acids are linked to the TCA cycle through certain TCA
cycle intermediates. If TCA cycle intermediates are
present in sufficient amounts, they can serve as precursors for the synthesis of amino acids. In contrast, when
energy production from glucose oxidation is compromised and TCA cycle intermediate levels become vulnerable, this can lead to increased protein degradation

to provide amino acids into the TCA cycle. As seen in
Fig. 6, the amino acids that changed are all significantly
higher in iMSBmal1−/− mice. Since multiple lines of
evidence suggest that glucose oxidation is blunted in
iMSBmal1−/−mice, it is probable that the skeletal muscle
is relying on alternate energy sources such as protein and
fat. The fact that citrate and isocitrate in iMSBmal1−/−
GTN are reduced supports a shift in substrate utilization.
In healthy muscle, pyruvate generated from glycolysis may
enter the TCA cycle as acetyl CoA at oxaloacetate and
then the TCA cycle proceeds [23]. Citrate and isocitrate
are products generated during the initial steps of the TCA
cycle. Glucose oxidation would generate these while fatty
acid and amino acid oxidation enter the TCA cycle downstream of these events.
In light of the fact that skeletal muscle, a vital metabolic
tissue, cannot efficiently dispose of glucose and utilize it as
a fuel source, one can expect that this would impact overall
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metabolic health. While remarkable that loss of a single
gene is the skeletal muscle is sufficient to alter systems metabolism, it is not unprecedented as muscle-specific Glut4
knockout mice gain weight more slowly and have reduced
fat stores [37]. This change in glucose metabolism in
skeletal muscle likely drives oxidation of fat in adipose
tissue resulting in leaner mice. This same study and some
studies utilizing hexokinase- and phosphofructokinasedeficient mice demonstrate development of insulin resistance, glucose intolerance, and elevated blood insulin with
disruption of glycolytic flux [9, 22, 37].

Conclusions
The findings of this study highlight the novel role(s) for
skeletal muscle Bmal1 in regulating tissue glucose metabolism (i.e., decreased GLUT4 and glycolytic enzymes),
substrate utilization (i.e., changes in citrate to isocitrate
within the TCA cycle), as well as system homeostasis
(i.e., hyperglycemia in the non-fasting condition, glucose
intolerance, and altered body composition). However,
there is still much that is unknown. Further research is
required to elucidate the exact mechanism by which
Bmal1 alters GLUT4 content, glucose uptake, and glycolytic gene expression and activity in the skeletal muscle.
We demonstrate that skeletal muscle Bmal1 is critical
for skeletal muscle carbohydrate metabolism and disruptions in glucose oxidation, and subsequent compensations impact overall metabolic health. Targeting the
molecular clock mechanism provides a novel approach
for future treatment modalities in the treatments of diabetes and metabolic disease.
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